Equity · Healthcare
WVE
NASDAQWave Life Sciences (WVE)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for WVE to draw a line in its place.
- Market cap
- 1.1B USD
- Revenue, year to Dec 2025
- 42.7M USD
- EPS, diluted, year to Dec 2025
- −1.21 USD
- 52-week range
- 5.65 USD – 21 USD
- Avg volume
- 768.7K
as of Jul 17, 2026
Have Wave Life Sciences (WVE) insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Wave Life Sciences insiders reported 4 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 30 Mar 2026.
Form 4, 90 days to 9 Nov 2026, newest reported trade 12 Aug 2026
Buys 0Sells 4Net sold $135KOther filings 9
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 12 Aug 2026 | Rawcliffe AdrianDirector | Sell | 12,700 | 67K USD |
| 11 Aug 2026 | Wagner Heidi LDirector | Sell | 7,000 | 42K USD |
| 11 Aug 2026 | TAKANASHI KENDirector | Sell | 3,864 | 23K USD |
| 11 Aug 2026 | Tan Aik NaDirector | Sell | 432 | 3K USD |
| Sold | 4 open-market sales | 23,996 | $135K |
9 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 05 Oct 2026 | RA CAPITAL MANAGEMENT, L.P.Director | Award | 10,700 | |
| 05 Oct 2026 | Verdine Gregory L.Director | Award | 10,700 | |
| 05 Oct 2026 | Tan Aik NaDirector | Award | 10,700 | |
| 05 Oct 2026 | TAKANASHI KENDirector | Award | 10,700 | |
| 05 Oct 2026 | CORRIGAN MARKDirector | Award | 10,700 | |
| 05 Oct 2026 | Rawcliffe AdrianDirector | Award | 10,700 | |
| 05 Oct 2026 | HENRY CHRISTIAN ODirector | Award | 10,700 | |
| 05 Oct 2026 | Wagner Heidi LDirector | Award | 10,700 | |
| 11 Aug 2026 | Wagner Heidi LDirector | Option exercise | 7,000 | 42K USD |
Which funds hold Wave Life Sciences (WVE)?
12 of the 45 institutional funds we track reported a Wave Life Sciences position for the quarter ended 30 Jun 2026 — a combined 147.5M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Maverick Capital | Held (±25%) | 10,278,115 | 59.7M USD | +1.1% |
| Two Sigma Investments | Added | 3,707,686 | 21.5M USD | +97.4% |
| Millennium Management | Added | 1,811,282 | 10.5M USD | +86.3% |
| D. E. Shaw & Co. | Added | 1,772,228 | 10.3M USD | +2,351.0% |
| Renaissance Technologies | Added | 1,704,520 | 9.9M USD | +185.4% |
| AQR Capital Management | Added | 1,648,045 | 9.6M USD | +265.3% |
| Point72 Asset Management | New position | 1,484,989 | 8.6M USD | |
| Marshall Wace | Trimmed | 999,533 | 5.8M USD | −44.2% |
| Baker Bros. Advisors | Held (±25%) | 822,638 | 4.8M USD | |
| Man Group | Added | 505,456 | 2.9M USD | +689.3% |
Showing the 10 largest of 12 reported positions. The figures above count all of them.
What has been filed or recorded for Wave Life Sciences (WVE)?
The filings we hold for Wave Life Sciences, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 13,933 shares | 46K USD notional · 0.007% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.30 USD | |
| 30 Sep 2026 | Financials | Total assets | 507.9M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 401.9M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.34 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.13 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −1.21 USD | |
| 31 Dec 2025 | Financials | Revenue | 42.7M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −204.4M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −1.21 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.32 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.31 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.29 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −0.70 USD |
Wave Life Sciences (WVE): frequently asked questions
What is Wave Life Sciences’ market cap?
Wave Life Sciences is worth 1.1B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.
What is Wave Life Sciences’ revenue?
Wave Life Sciences reported revenue of 42.7M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Wave Life Sciences insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Wave Life Sciences insiders reported 4 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 30 Mar 2026. A further 9 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Wave Life Sciences?
12 of the 45 funds we track reported a Wave Life Sciences position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Maverick Capital, Two Sigma Investments and Millennium Management. See Funds
When did Wave Life Sciences last report earnings?
Wave Life Sciences last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.30 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings